- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT00321685
Bevacizumab, Radiation Therapy, and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Nonmetastatic Rectal Cancer
Phase II Study of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin and Bevacizumab Followed by Surgery and Postoperative 5-FU, Leucovorin, Oxaliplatin (FOLFOX) and Bevacizumab in Patients With Locally Advanced Rectal Cancer
Przegląd badań
Status
Szczegółowy opis
PRIMARY OBJECTIVES:
I. To evaluate the pathological complete response rate in patients with T3 and T4 rectal cancers when treated preoperatively with capecitabine, oxaliplatin, bevacizumab, and concurrent radiotherapy (XRT).
II. To evaluate the resection rate for T3 and T4 rectal cancers and the expected versus actual type of resection (abdominoperinal resection [APR] vs. low anterior resection [LAR] vs. LAR/coloanal anastomosis).
III. To make preliminary observations of patient survival and patterns of recurrence for this treatment combination.
IV. To gain additional experience regarding the toxicity and tolerability of this preoperative and postoperative regimen.
OUTLINE:
PREOPERATIVE CHEMORADIOTHERAPY: Patients undergo radiotherapy (total dose to the tumor bed was 5040 cGy) once daily (QD) 5 days a week and receive capecitabine 825 mg/m^2 orally (PO) twice daily (BID) 5 days a week for 5.5 weeks. Patients also receive oxaliplatin 50 mg/m^2 intravenously (IV) over 2 hours on days 1, 8, 15, 22, and 29 and bevacizumab 5 mg/kg IV over 30-90 minutes on days 1, 15, and 29 during radiotherapy.
SURGERY: Approximately 6-8 weeks after completion of chemoradiotherapy, patients undergo surgical resection. Patients whose tumors are not completely resected or who have metastatic disease discontinue protocol therapy.
POSTOPERATIVE CHEMOTHERAPY: Approximately 4-12 weeks after surgery, patients receive oxaliplatin IV over 2 hours, leucovorin calcium 400 mg/m^2 IV over 2 hours, and bevacizumab 5 mg/kg IV over 30-90 minutes on day 1. Patients also receive fluorouracil 2400 mg/m^2 IV continuously over 46 hours beginning on day 1. Treatment repeats every 2 weeks for 9 courses in the absence of disease progression or unacceptable toxicity. Patients then receive up to 3 additional courses of leucovorin calcium, fluorouracil, and bevacizumab.
After completion of study treatment, patients are followed up periodically for 10 years.
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Faza 2
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Alabama
-
Birmingham, Alabama, Stany Zjednoczone, 35233
- University of Alabama at Birmingham Cancer Center
-
-
Connecticut
-
New Britain, Connecticut, Stany Zjednoczone, 06050
- The Hospital of Central Connecticut
-
-
Georgia
-
Atlanta, Georgia, Stany Zjednoczone, 30322
- Emory University Hospital/Winship Cancer Institute
-
Decatur, Georgia, Stany Zjednoczone, 30033
- Atlanta VA Medical Center
-
Macon, Georgia, Stany Zjednoczone, 31201
- Medical Center of Central Georgia
-
-
Illinois
-
Aurora, Illinois, Stany Zjednoczone, 60504
- Rush - Copley Medical Center
-
Berwyn, Illinois, Stany Zjednoczone, 60402
- MacNeal Hospital and Cancer Center
-
Chicago, Illinois, Stany Zjednoczone, 60611
- Northwestern University
-
Chicago, Illinois, Stany Zjednoczone, 60625
- Swedish Covenant Hospital
-
Chicago, Illinois, Stany Zjednoczone, 60611
- Hematology and Oncology Associates
-
Chicago, Illinois, Stany Zjednoczone, 60657
- Presence Saint Joseph Hospital-Chicago
-
Chicago, Illinois, Stany Zjednoczone, 60612
- Jesse Brown Veterans Affairs Medical Center
-
Chicago, Illinois, Stany Zjednoczone, 60616
- Mercy Hospital and Medical Center
-
Effingham, Illinois, Stany Zjednoczone, 62401
- Saint Anthony Memorial Hospital
-
Highland Park, Illinois, Stany Zjednoczone, 60035
- Hematology Oncology Associates of Illinois-Highland Park
-
Hinsdale, Illinois, Stany Zjednoczone, 60521
- Hinsdale Hematology Oncology Associates Incorporated
-
Joliet, Illinois, Stany Zjednoczone, 60435
- Joliet Oncology-Hematology Associates Limited
-
Joliet, Illinois, Stany Zjednoczone, 60432
- Midwest Center for Hematology Oncology
-
Libertyville, Illinois, Stany Zjednoczone, 60048
- NorthShore Hematology Oncology-Libertyville
-
Moline, Illinois, Stany Zjednoczone, 61265
- Garneau, Stewart C MD (UIA Investigator)
-
Moline, Illinois, Stany Zjednoczone, 61265
- Porubcin, Michael MD (UIA Investigator)
-
Moline, Illinois, Stany Zjednoczone, 61265
- Spector, David MD (UIA Investigator)
-
Moline, Illinois, Stany Zjednoczone, 61265
- Trinity Medical Center
-
Moline, Illinois, Stany Zjednoczone, 61265
- Sharis, Christine M MD (UIA Investigator)
-
Moline, Illinois, Stany Zjednoczone, 61265
- Stoffel, Thomas J MD (UIA Investigator)
-
Moline, Illinois, Stany Zjednoczone, 61265
- Vigliotti, Antonio, P.G. M.D. (UIA Investigator)
-
Naperville, Illinois, Stany Zjednoczone, 60563
- DuPage Medical Group-Ogden
-
Niles, Illinois, Stany Zjednoczone, 60714
- Illinois Cancer Specialists-Niles
-
Skokie, Illinois, Stany Zjednoczone, 60076
- Hematology Oncology Associates of Illinois - Skokie
-
Skokie, Illinois, Stany Zjednoczone, 60076
- Edward H Kaplan MD and Associates
-
Urbana, Illinois, Stany Zjednoczone, 61801
- Carle Cancer Center
-
-
Indiana
-
Michigan City, Indiana, Stany Zjednoczone, 46360
- Franciscan Saint Anthony Health-Michigan City
-
-
Iowa
-
Bettendorf, Iowa, Stany Zjednoczone, 52722
- Constantinou, Costas L MD (UIA Investigator)
-
Sioux City, Iowa, Stany Zjednoczone, 51101
- Siouxland Regional Cancer Center
-
Sioux City, Iowa, Stany Zjednoczone, 51102
- Mercy Medical Center-Sioux City
-
Sioux City, Iowa, Stany Zjednoczone, 51104
- Saint Luke's Regional Medical Center
-
-
Michigan
-
Kalamazoo, Michigan, Stany Zjednoczone, 49007
- West Michigan Cancer Center
-
Kalamazoo, Michigan, Stany Zjednoczone, 49007
- Bronson Methodist Hospital
-
Kalamazoo, Michigan, Stany Zjednoczone, 49048
- Borgess Medical Center
-
-
Minnesota
-
Burnsville, Minnesota, Stany Zjednoczone, 55337
- Fairview Ridges Hospital
-
Coon Rapids, Minnesota, Stany Zjednoczone, 55433
- Mercy Hospital
-
Edina, Minnesota, Stany Zjednoczone, 55435
- Fairview-Southdale Hospital
-
Fridley, Minnesota, Stany Zjednoczone, 55432
- Unity Hospital
-
Hutchinson, Minnesota, Stany Zjednoczone, 55350
- Hutchinson Area Health Care
-
Litchfield, Minnesota, Stany Zjednoczone, 55355
- Meeker County Memorial Hospital
-
Maplewood, Minnesota, Stany Zjednoczone, 55109
- Saint John's Hospital - Healtheast
-
Maplewood, Minnesota, Stany Zjednoczone, 55109
- Minnesota Oncology Hematology PA-Maplewood
-
Minneapolis, Minnesota, Stany Zjednoczone, 55415
- Hennepin County Medical Center
-
Minneapolis, Minnesota, Stany Zjednoczone, 55407
- Abbott-Northwestern Hospital
-
Minneapolis, Minnesota, Stany Zjednoczone, 55407
- Virginia Piper Cancer Institute
-
Robbinsdale, Minnesota, Stany Zjednoczone, 55422
- North Memorial Medical Health Center
-
Saint Louis Park, Minnesota, Stany Zjednoczone, 55416
- Park Nicollet Clinic - Saint Louis Park
-
Saint Louis Park, Minnesota, Stany Zjednoczone, 55416
- Metro Minnesota Community Oncology Research Consortium
-
Saint Paul, Minnesota, Stany Zjednoczone, 55101
- Regions Hospital
-
Saint Paul, Minnesota, Stany Zjednoczone, 55102
- United Hospital
-
Saint Paul, Minnesota, Stany Zjednoczone, 55102
- Saint Joseph's Hospital - Healtheast
-
Shakopee, Minnesota, Stany Zjednoczone, 55379
- Saint Francis Regional Medical Center
-
Waconia, Minnesota, Stany Zjednoczone, 55387
- Ridgeview Medical Center
-
Woodbury, Minnesota, Stany Zjednoczone, 55125
- Minnesota Oncology Hematology PA-Woodbury
-
Woodbury, Minnesota, Stany Zjednoczone, 55125
- Woodwinds Health Campus
-
-
Nebraska
-
Lincoln, Nebraska, Stany Zjednoczone, 68510
- Nebraska Cancer Research Center
-
Omaha, Nebraska, Stany Zjednoczone, 68124
- Alegent Health Bergan Mercy Medical Center
-
Omaha, Nebraska, Stany Zjednoczone, 68122
- Alegent Health Immanuel Medical Center
-
Omaha, Nebraska, Stany Zjednoczone, 68131
- Creighton University Medical Center
-
Omaha, Nebraska, Stany Zjednoczone, 68106
- Missouri Valley Cancer Consortium
-
-
New Jersey
-
Mount Holly, New Jersey, Stany Zjednoczone, 08060
- Virtua Memorial
-
Sparta, New Jersey, Stany Zjednoczone, 07871
- Sparta Cancer Treatment Center
-
Voorhees, New Jersey, Stany Zjednoczone, 08043
- Virtua Voorhees
-
Woodbury, New Jersey, Stany Zjednoczone, 08096
- Inspira Medical Center Woodbury
-
-
New York
-
Bronx, New York, Stany Zjednoczone, 10467
- Montefiore Medical Center - Moses Campus
-
Bronx, New York, Stany Zjednoczone, 10466
- Montefiore Medical Center-Wakefield Campus
-
-
Ohio
-
Akron, Ohio, Stany Zjednoczone, 44304
- Summa Akron City Hospital/Cooper Cancer Center
-
Barberton, Ohio, Stany Zjednoczone, 44203
- Summa Barberton Hospital
-
Bellefontaine, Ohio, Stany Zjednoczone, 43311
- Mary Rutan Hospital
-
Chillicothe, Ohio, Stany Zjednoczone, 45601
- Adena Regional Medical Center
-
Columbus, Ohio, Stany Zjednoczone, 43214
- Riverside Methodist Hospital
-
Columbus, Ohio, Stany Zjednoczone, 43228
- Doctors Hospital
-
Columbus, Ohio, Stany Zjednoczone, 43215
- Grant Medical Center
-
Columbus, Ohio, Stany Zjednoczone, 43222
- Mount Carmel Health Center West
-
Delaware, Ohio, Stany Zjednoczone, 43015
- Grady Memorial Hospital
-
Lancaster, Ohio, Stany Zjednoczone, 43130
- Fairfield Medical Center
-
Lima, Ohio, Stany Zjednoczone, 45801
- Saint Rita's Medical Center
-
Marietta, Ohio, Stany Zjednoczone, 45750
- Marietta Memorial Hospital
-
Newark, Ohio, Stany Zjednoczone, 43055
- Licking Memorial Hospital
-
Springfield, Ohio, Stany Zjednoczone, 45505
- Springfield Regional Medical Center
-
Westerville, Ohio, Stany Zjednoczone, 43081
- Saint Ann's Hospital
-
Zanesville, Ohio, Stany Zjednoczone, 43701
- Genesis Healthcare System Cancer Care Center
-
-
Oklahoma
-
Tulsa, Oklahoma, Stany Zjednoczone, 74136
- Natalie Warren Bryant Cancer Center at Saint Francis
-
-
Pennsylvania
-
Allentown, Pennsylvania, Stany Zjednoczone, 18103
- Lehigh Valley Hospital-Cedar Crest
-
Darby, Pennsylvania, Stany Zjednoczone, 19023-1291
- Mercy Fitzgerald Hospital
-
East Stroudsburg, Pennsylvania, Stany Zjednoczone, 18301
- Pocono Medical Center
-
Ephrata, Pennsylvania, Stany Zjednoczone, 17522
- Ephrata Cancer Center
-
Media, Pennsylvania, Stany Zjednoczone, 19063
- Riddle Memorial Hospital
-
Philadelphia, Pennsylvania, Stany Zjednoczone, 19111
- Fox Chase Cancer Center
-
Philadelphia, Pennsylvania, Stany Zjednoczone, 19107
- Thomas Jefferson University Hospital
-
Philadelphia, Pennsylvania, Stany Zjednoczone, 19141
- Einstein Medical Center Philadelphia
-
Philadelphia, Pennsylvania, Stany Zjednoczone, 19114
- Aria Health-Torresdale Campus
-
Scranton, Pennsylvania, Stany Zjednoczone, 18508
- Hematology and Oncology Associates of North East Pennsylvania
-
Upland, Pennsylvania, Stany Zjednoczone, 19013
- Associates In Hematology Oncology PC-Upland
-
-
South Dakota
-
Sioux Falls, South Dakota, Stany Zjednoczone, 57105
- Avera Cancer Institute
-
Sioux Falls, South Dakota, Stany Zjednoczone, 57117-5134
- Sanford USD Medical Center - Sioux Falls
-
Sioux Falls, South Dakota, Stany Zjednoczone, 57104
- Sanford Cancer Center Oncology Clinic
-
Sioux Falls, South Dakota, Stany Zjednoczone, 57105
- Medical X-Ray Center
-
Sioux Falls, South Dakota, Stany Zjednoczone, 57105
- Avera McKennan Hospital and University Health Center
-
-
Texas
-
Dallas, Texas, Stany Zjednoczone, 75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
-
Wisconsin
-
La Crosse, Wisconsin, Stany Zjednoczone, 54601
- Gundersen Lutheran Medical Center
-
Milwaukee, Wisconsin, Stany Zjednoczone, 53226
- Froedtert and The Medical College of Wisconsin
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Patients must have histologically confirmed, locally advanced, non-metastatic primary T3 or T4 adenocarcinoma of the rectum
- Patients must not have evidence of tumor outside of the pelvis including liver metastases, peritoneal seeding, or metastatic inguinal lymphadenopathy
- Patients must not have intra-operative radiotherapy (IORT) or brachytherapy treatment to the pelvis
- The distal border of the tumor must be at or below the peritoneal reflection, defined as within 12 centimeters of the anal verge by proctoscopic examination
- Transmural penetration of tumor through the muscularis propria must be demonstrated by either of the following: computed tomography (CT) scan plus endorectal ultrasound, or a magnetic resonance imaging (MRI); an endorectal coil or pelvic MRI is allowed
- For the patient to be eligible, the surgeon must prospectively define the tumor as either initially resectable or potentially resectable after pre-operative chemoradiation; clinically resectable tumors are defined as completely resectable with negative margins based on routine examination of the non-anesthetized patient; patients whose tumors are not resectable are not eligible; before pre-operative (op) treatment, the surgeon should estimate and record the type of resection anticipated: pelvic exenteration, posterior pelvic exenteration, APR, LAR, or LAR/coloanal anastomosis
Patients with tumors that are clinically fixed, clinical stage T4N0-2, M0 are eligible if it is believed that their tumors are potentially resectable after chemoradiation; based on the following:
- Clinically fixed tumors on rectal examination with tumor adherent to the pelvic sidewall or sacrum
- Sciatica attributed to sacral root invasion with CT scan/MRI evidence of the lack of clear tissue plane will be considered evidence of fixation
- Hydronephrosis on CT scan or intravenous pyelogram (IVP) or ureteric or bladder invasion as documented by cystoscopy and cytology or biopsy, or invasion into prostate
- Vaginal or uterine involvement
- Patients must have Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- A surgical evaluation must confirm patient's ability to tolerate the proposed surgical procedure
- Patients must have a caloric intake > 1500 kilocalories/day (d)
- Within 4 weeks prior to registration, the patient's absolute neutrophil count (ANC) level must be >= 1,500/mm^3
- Within 4 weeks prior to registration, the patients platelet level must be >= 100,000/mm^3
- Within 4 weeks prior to registration, serum creatinine must be < 1.5 X upper limit of normal (ULN); if serum creatinine > 1.5 x ULN, then creatinine clearance must be >= 50 mL/mm
- Within 4 weeks prior to registration, serum bilirubin must be =< 1.5 X ULN
- Within 4 weeks prior to registration, alkaline phosphatase (alk phos) must be < 2 x ULN
- Within 4 weeks prior to registration, serum glutamic oxaloacetic transaminase (SGOT) must be < 2 x ULN
- Carcinoembryonic antigen (CEA) must be determined prior to initiation of therapy
- Within 4 weeks prior to registration, urine protein/creatinine (UPC) ratio must be < 1; patients with a ratio of >= 1 must undergo a 24-hour urine collection which must be an adequate collection and must demonstrate < 1 gram (gm) of protein in order to participate
- Within 4 weeks prior to registration, albumin must be >= 2 gm/dl
- Absence of clinical evidence of high-grade (lumen diameter < 1 cm) large bowel obstruction, unless diverting colostomy has been performed
- Eligible patients of reproductive potential (both sexes) must agree to use an accepted and effective method of contraceptive during study therapy and for at least 6 months after the completion of bevacizumab
- Women must not be pregnant or breast-feeding; all females of childbearing potential must have a serum pregnancy test to rule out pregnancy within 2 weeks of registration
- Patients must have had no prior chemotherapy for rectal cancer or pelvic irradiation therapy
- Patients with prior malignancies, including pelvic cancer, are eligible if they have been disease free for > 5 years; patients with prior in situ carcinomas are eligible provided there was complete removal
- Patients must have no active inflammatory bowel disease or other serious medical illness or disease that might limit the patient's ability to receive protocol therapy
- Patients with a history of cerebrovascular accident (CVA)/transient ischemic attack (TIA) at any time, or myocardial infarction/unstable angina within 12 months of study entry are not eligible
- Patients with > grade 1 peripheral neuropathy are not eligible
- Patients must have urine protein/creatinine (UPC) ratio of < 1.0; patients with a UPC ratio >= 1.0 must undergo a 24-hour urine collection, which must be an adequate collection and must demonstrate < 1 gm of protein in order to participate
- Patients with a history of hypertension must measure < 150/90 mmHg and be on a stable regimen of anti-hypertensive therapy
- Patients with clinically significant peripheral vascular disease are not eligible
Patients must not have any of the following:
- Unstable angina (within 12 months of study entry)
- New York Heart Association (NYHA) grade II or higher congestive heart failure
- Evidence of bleeding diathesis/coagulopathy
- Serious non-healing wound or bone fracture
Patients with a history of the following within 28 days prior to registration are not eligible:
- Abdominal fistula
- Gastrointestinal perforation
- Intrabdominal abscess
Patients with a history of the following within 28 days prior to day 0 (first treatment day) are not eligible:
- Major surgical procedure
- Open biopsy
- Significant traumatic injury
- Patients must not have core biopsy within 7 days prior to day 0 (first treatment day)
Patients with prothrombin time (PT) (international normalized ratio [INR]) > 1.5 are not eligible, unless the patient is on full-dose anticoagulants; if so, the following criteria must be met for enrollment:
- The subject must have an in-range INR (usually between 2 and 3), be on a stable dose of warfarin or on a stable dose of low molecular weight heparin
- The subject must not have active bleeding or a pathological condition that is associated with a high risk of bleeding
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Nie dotyczy
- Model interwencyjny: Zadanie dla jednej grupy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
---|---|
Eksperymentalny: Treatment (bevacizumab and chemoradiotherapy)
See Detailed Description
|
Biorąc pod uwagę IV
Inne nazwy:
Biorąc pod uwagę IV
Inne nazwy:
Biorąc pod uwagę IV
Inne nazwy:
Biorąc pod uwagę PO
Inne nazwy:
Biorąc pod uwagę IV
Inne nazwy:
Poddaj się resekcji chirurgicznej
Poddaj się radioterapii
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Pathologic Complete Response Rate
Ramy czasowe: Assessed at surgery time
|
Pathologic complete response to preoperative therapy was determined at the time of surgical resection.
Pathologic complete response (pCR) is defined as no evidence of invasive cells on pathologic examination of the primary rectal cancer (or tissue from the area where the tumor had been if there is a complete clinical response).
Pathologic complete response rate is calculated as number of patients achieving pathologic complete response divided by all eligible and treated patients
|
Assessed at surgery time
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Resection Rate for T3 Rectal Cancers
Ramy czasowe: Assessed at surgery time
|
Resection rate is defined as number of patients with T3 rectal cancer who underwent curative surgical resection among all eligible and treated patients with T3 rectal cancers
|
Assessed at surgery time
|
Resection Rate for T4 Rectal Cancers
Ramy czasowe: Assessed at surgery time
|
Resection rate is defined as number of patients with T4 rectal cancer who underwent curative surgical resection among all eligible and treated patients with T4 rectal cancers
|
Assessed at surgery time
|
5-year Overall Survival Rate
Ramy czasowe: survival follow-up began after post-operative chemotherapy, assessed every 3 months for patients 3-5 years from registration, every 6 months for patients 5-10 years from registration and every 12 months for patients 10 years from registration
|
Overall survival is defined as time from registration to death from any cause.
5-year overall survival rate is estimated using Kaplan-Meier method.
|
survival follow-up began after post-operative chemotherapy, assessed every 3 months for patients 3-5 years from registration, every 6 months for patients 5-10 years from registration and every 12 months for patients 10 years from registration
|
5-year Recurrence-free Survival Rate
Ramy czasowe: recurrence follow-up began after post-operative chemotherapy, assessed every 3 months for patients 3-5 years from registration, every 6 months for patients 5-10 years from registration and every 12 months for patients 10 years from registration
|
Recurrence free survival is defined as time from surgery to disease recurrence or death without recurrence (whichever occurred first) among resected patients.
5-year recurrence-free survival rate is estimated using Kaplan-Meier method, with 90% confidence interval calculated using Greenwood's formula.
|
recurrence follow-up began after post-operative chemotherapy, assessed every 3 months for patients 3-5 years from registration, every 6 months for patients 5-10 years from registration and every 12 months for patients 10 years from registration
|
Współpracownicy i badacze
Sponsor
Śledczy
- Główny śledczy: Jerome C Landry, ECOG-ACRIN Cancer Research Group
Publikacje i pomocne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
- Choroby Układu Pokarmowego
- Nowotwory
- Nowotwory według lokalizacji
- Nowotwory przewodu pokarmowego
- Nowotwory Układu Pokarmowego
- Choroby przewodu pokarmowego
- Choroby jelit
- Nowotwory jelit
- Choroby odbytu
- Nowotwory jelita grubego
- Nowotwory odbytnicy
- Fizjologiczne skutki leków
- Molekularne mechanizmy działania farmakologicznego
- Antymetabolity, przeciwnowotworowe
- Antymetabolity
- Środki przeciwnowotworowe
- Środki immunosupresyjne
- Czynniki immunologiczne
- Środki ochronne
- Inhibitory angiogenezy
- Środki modulujące angiogenezę
- Substancje wzrostowe
- Inhibitory wzrostu
- Mikroelementy
- Witaminy
- Środki konserwujące gęstość kości
- Hormony i środki regulujące wapń
- Odtrutki
- Kompleks witamin B
- Hematynika
- Przeciwciała
- Fluorouracyl
- Kapecytabina
- Oksaliplatyna
- Immunoglobuliny
- Bewacyzumab
- Leukoworyna
- Wapń
- Lewoleukoworyna
- Przeciwciała, monoklonalne
- Środki przeciwnowotworowe, immunologiczne
- Kwas foliowy
- Wapń, dietetyczny
- Immunoglobulina G
- Czynniki wzrostu śródbłonka
Inne numery identyfikacyjne badania
- NCI-2009-01081 (Identyfikator rejestru: CTRP (Clinical Trial Reporting Program))
- U10CA180820 (Grant/umowa NIH USA)
- U10CA021115 (Grant/umowa NIH USA)
- CDR0000471148
- ECOG-E3204
- E3204 (Inny identyfikator: CTEP)
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Bewacyzumab
-
Dana-Farber Cancer InstituteBristol-Myers Squibb; Genentech, Inc.ZakończonyCzerniakStany Zjednoczone
-
National Cancer Institute (NCI)Aktywny, nie rekrutującyNawracający rak jajowodu | Nawracający rak jajnika | Nawracający pierwotny rak otrzewnej | Cystadenocarcinoma jasnokomórkowego jajnika | Gruczolakorak endometrioidalny jajnika | Serous Cystadenocarcinoma jajnika | Gruczolakorak jasnokomórkowy endometrium | Gruczolakorak surowiczy endometrium | Nawracający... i inne warunkiStany Zjednoczone
-
National Cancer Institute (NCI)NRG OncologyZakończonyGlejaka wielopostaciowego | Glejak | Nawracający glejak wielopostaciowy | Skąpodrzewiak | Glejak olbrzymiokomórkowy | Nawracający nowotwór mózguStany Zjednoczone, Kanada
-
M.D. Anderson Cancer CenterRekrutacyjnyRak wątrobowokomórkowy w stadium IB AJCC v8 | Rak wątrobowokomórkowy II stopnia AJCC v8 | Resekcyjny rak wątrobowokomórkowy | Rak wątrobowokomórkowy stopnia I AJCC v8 | Rak wątrobowokomórkowy w stadium IA AJCC v8Stany Zjednoczone
-
Mayo ClinicNational Cancer Institute (NCI)Aktywny, nie rekrutującyZłośliwy nowotwór lity | Gruczolakorak endometrioidalny jajnika | Niezróżnicowany rak jajnika | Gruczolakorak szyjki macicy | Rak gruczolakowaty szyjki macicy | Nowotwór złośliwy otrzewnej | Gruczolakorak jasnokomórkowy endometrium | Endometrialny gruczolakorak endometrioidalny | Mieszany gruczolakokomórkowy... i inne warunkiStany Zjednoczone
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); Merck Sharp & Dohme LLC; Celldex TherapeuticsRekrutacyjnyNawracający rak jajowodu | Nawracający rak jajnika | Nawracający pierwotny rak otrzewnej | Nawracający gruczolakorak surowiczy endometrium | Rak jasnokomórkowy jajnika | Nawrotowy rak jajnika oporny na platynę | Rak jajnika wrażliwy na platynę | Nawracający gruczolakorak endometrioidalny jajowodu | Nawracający... i inne warunkiStany Zjednoczone
-
National Cancer Institute (NCI)ZakończonyGruczolakorak szyjki macicy | Rak gruczolakowaty szyjki macicy | Rak płaskonabłonkowy szyjki macicy, gdzie indziej niesklasyfikowany | Rak szyjki macicy w stadium IVA AJCC v6 i v7 | Nawracający rak szyjki macicy | Rak szyjki macicy stopnia IV AJCC v6 i v7 | Rak szyjki macicy w stadium IVB AJCC v6 i v7Stany Zjednoczone
-
Northwestern UniversityNational Cancer Institute (NCI); Ipsen BiopharmaceuticalsZakończonyNawracający rak jajowodu | Nawracający rak jajnika | Nawracający pierwotny rak otrzewnej | Platynooporny rak jajowodu | Platynooporny pierwotny rak otrzewnej | Platynooporny rak jajnika | Oporny rak jajnika | Oporny na leczenie rak jajowodu | Oporny na leczenie pierwotny rak otrzewnejStany Zjednoczone
-
M.D. Anderson Cancer CenterAktywny, nie rekrutującyNiedrobnokomórkowy rak płuc z przerzutami | Rak płuc w stadium IVA AJCC v8 | Rak płuc w stadium IVB AJCC v8 | Rak płuc w stadium IV AJCC v8 | Rak płuc w stadium IIIC AJCC v8 | Nawracający niedrobnokomórkowy rak płucStany Zjednoczone
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RekrutacyjnyNawracający rak jajowodu | Nawracający rak jajnika | Nawracający pierwotny rak otrzewnej | Gruczolakorak endometrioidalny jajnika | Rak jasnokomórkowy jajnika | Rak jasnokomórkowy jajowodu | Gruczolakorak endometrioidalny jajowodu | Rak surowiczy jajowodu | Gruczolakorak surowiczy jajnika | Pierwotny gruczolakorak... i inne warunkiStany Zjednoczone